002653:SZSEHaisco Pharmaceutical Group Co. Ltd. Class A Analysis

Haisco Pharmaceutical is trading at CNY 47.12, just below its 20‑day SMA (47.16) and well under the 50‑day (50.22) and 200‑day (51.49) averages, signaling a bearish price trajectory despite a modestly bullish MACD histogram. Volume is on an upward trend, yet the 30‑day volatility of roughly 44% and an almost neutral beta indicate high idiosyncratic risk. The valuation metrics are extreme: a trailing P/E of 174 versus an industry average of 27, a price‑to‑book of 13.5, and a DCF‑derived fair value of only CNY 12.7, implying the stock is markedly overvalued. Dividend yield sits at 1.28% but the payout ratio is near 99% while free cash flow is negative, raising concerns about dividend sustainability.
On the fundamentals side, revenue surged 22% to CNY 4.27 bn with a strong gross margin of 72.6%, yet operating cash flow is modest and the balance sheet shows a debt‑to‑equity of 55% and a negative free cash flow. The recent $1 bn‑plus licensing deal for the innovative drug HSK39004 could provide a future growth catalyst, but the upside is largely speculative given the current pricing gap. Overall, the stock faces a clash between high growth potential and severe overvaluation, demanding caution.